Clinical trials: Nutritional Evaluation
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Amyloidosis
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
The study will be conducted in two parts. The first (Part A) will be an open label single dose escalation part beginning with the proposed starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1…
- Trial name
- NCT01777243
- Testing
- GSK2398852, GSK2315698
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker 2. To evaluate the safety of Cilostazol and Probucol alone and in combination on atherosclerosis related…
- Trial name
- NCT00823849
- Testing
- Cilostazol, Probucol, Cilostazol+Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Otsuka Beijing Research Institute
Leber Congenital Amaurosis 10, Blindness
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- ILLUMINATE (NCT03913143)
- Testing
- sepofarsen
- Where
- 14 sites in United States, Belgium and 7 more
- Volunteers
- 36 people
- Sponsor
- ProQR Therapeutics
Obese, Healthy
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225
- Trial name
- NCT05835752
- Testing
- RAY1225
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Type 2 Diabetes Mellitus
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients
The purpose of this study is to compare the effect on glucose control of 3 different AZD1656 dosing regimens with placebo in Japanese type 2 diabetes mellitus (T2DM) patients, as evaluated by the change in HbA1c from baseline to…
- Trial name
- NCT01152385
- Testing
- AZD1656
- Where
- 3 sites in Japan
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
This study is an open-label, randomized, fed, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-393 in healthy subjects
- Trial name
- NCT04260438
- Testing
- CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T, CKD-393 0.5/100/1000mg formulation 1 Tab. 1T, CKD-393 0.5/100/1000mg formulation 2 Tab. 1T
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral antidiabetic drugs in type 2…
- Trial name
- SOLVE™ (NCT00825643)
- Testing
- insulin detemir
- Where
- 9 sites in Canada, China and 7 more
- Volunteers
- 18,481 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effect of BKR-013 on Average Daily Glucose Levels
The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration.
- Trial name
- NCT03382015
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- BioKier Inc.
Diabetes Mellitus, Type 2
A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the body does to the medication) and pharmacodynamics (what the medication does to the body) of treatment with JNJ-41443532 relative to…
- Trial name
- NCT01230749
- Testing
- JNJ-41443532, Pioglitazone 30 mg
- Volunteers
- 89 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 1 Diabetes
Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System
The purpose of this study is to evaluate the safety and effectiveness of the MEDTRUM Hybrid Closed Loop (HCL) System in children, adolescents, and adults with type 1 diabetes (7-75 years old) in a home setting and to test the…
- Trial name
- SEECLOOP (NCT06363916)
- Testing
- Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation
- Where
- 17 sites in France
- Volunteers
- 160 people
- Sponsor
- Medtrum France
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypercholesterolemia
A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia
The purpose of this study is to evaluate the safety of BMS-852927 after 28 days of dosing in patients with high cholesterol.
- Trial name
- NCT01651273
- Testing
- BMS-852927
- Where
- 8 sites in Canada, Germany
- Volunteers
- 97 people
- Sponsor
- Bristol-Myers Squibb
Cockayne Syndrome
Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome
This study is to compare the exposure of orally administered Prodarsan to the intravenous dosed Osmitrol (10% solution) in Cockayne Syndrome (CS) patients.
- Trial name
- NCT01142154
- Testing
- Prodarsan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- DNage B.V.
Diabetes Mellitus
Evaluation of GLUCOFACTS® Deluxe Diabetes Management System
The purpose of this study is to evaluate a Diabetes management program in the hands of potential users, both health care professionals and lay persons.
- Trial name
- NCT00892151
- Testing
- GLUCOFACTS® Deluxe
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus, Type 2
Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
Primary objective: To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients Secondary objectives: To assess the forced titration on physician and patient satisfaction To evaluate…
- Trial name
- LANTIT (NCT00701831)
- Testing
- Insulin glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Hyperglycemia
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01719003
- Testing
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd
- Where
- 190 sites in United States, Brazil and 19 more
- Volunteers
- 1,413 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension
To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.
- Trial name
- NCT00790153
- Testing
- Insulin, AZD1656
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral…
- Trial name
- NCT00437112
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Non-hypovolemic Non-acute Hyponatremia
Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
This drug has been developed to treat Hyponatremia. The primary purpose of this study is to verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15, 30, and 60 mg or placebo in patients with…
- Trial name
- NCT01507727
- Testing
- Tolvaptan
- Where
- 3 sites in China
- Volunteers
- 240 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.